Darier Disease Market Share, Size, Trends, Industry Analysis Report, By Treatment (Medication, Surgery, and Others); By Application; By End- User; By Region; Segment Forecast, 2023-2032
- Published Date:Jun-2023
- Pages: 112
- Format: PDF
- Report ID: PM3363
- Base Year: 2022
- Historical Data: 2019-2021
Report Outlook
The global Darier disease market was valued at USD 46.21 million in 2022 and is expected to grow at a CAGR of 4.9% during the forecast period. Darier disease market is expected to grow significantly in the coming years, driven by increasing awareness of the disease and advancements in genetic testing and personalized medicine. Darier disease, also known as Darier-White disease or keratosis follicularis, is a rare genetic skin disorder that affects about 1 in 30,000 individuals worldwide. It is caused by mutations in the ATP2A2 gene, which is responsible for encoding the SERCA2 protein, which is crucial in regulating the calcium levels within cells. The disorder is characterized by the development of dark, scaly patches, bumps, and cysts on the skin, especially on the chest, back, scalp, forehead, and nails. The low patient population and high development costs for medicines for uncommon diseases may limit the number of companies investing in this area.
To Understand More About this Research: Request a Free Sample Report
However, numerous pharmaceutical companies are actively studying and developing innovative therapeutics for Darier disease market, including gene therapies, small molecule inhibitors, and monoclonal antibodies.
Furthermore, the market is likely to face challenges such as a limited patient population, high cost of therapy, and regulatory hurdles. Nevertheless, the potential benefits of new treatments for Darier disease are significant, and continued investment in research and development is likely to yield promising results.
The COVID-19 pandemic has substantially influenced the healthcare sector, with many facilities and professionals concentrating on treating COVID-19 patients. Several medical illnesses, particularly uncommon diseases like Darier disease, have experienced delays in their identification and treatment. Overall, the COVID-19 pandemic has had a complicated and multidimensional influence on the market for treatments for Darier's illness, and the long-term repercussions are still unknown. Patients with Darier disease must maintain continuous communication with their medical team to manage their condition throughout pandemic.
For Specific Research Requirements, Speak With the Research Analyst
Industry Dynamics
Growth Drivers
Darier disease is a rare disorder, and the prevalence of the disease is increasing due to improved diagnosis and genetic testing. This is likely to drive demand for new therapies in the coming years. Additionally, one of the major factors boosting the market's expansion is the rising demand for sophisticated dermatological diagnoses for drier diseases. The diagnostic techniques and imaging technologies used in dermatology have advanced significantly, each with advantages and restrictions. Also, technological improvements are aimed at improving the sensitivity and accuracy of the detecting mechanisms in dermatological diagnosis.
For instance, a research report by Ana Maria Malciu et al. published in 2022 claims that most of these artificial intelligence technologies have already achieved clinician-level precision in the identification of numerous skin illnesses, and in several trials, machine accuracy has even surpassed them. The potential for additional study into the automated RCM image analysis process is thus evident.
Report Segmentation
The market is primarily segmented based on treatment, application, end- user and region.
|
By Treatment |
By Application |
By End- User |
By Region |
|
|
|
|
To Understand the Scope of this Report: Speak to Analyst
Surgery is expected to dominate the industry's market sector during forecast period
Surgery will dominate the market in the projected period. The key driver of the market is the scarcity of Darier disease treatments. Additionally, the primary factor driving the growth of the surgical industry is its ability to reduce pain and discomfort while enhancing results. Dermabrasion, laser treatment, or surgical excision are options for managing recalcitrant diseases.
Laser therapy for treating Darier disease is controversial, as its effectiveness in improving skin conditions and symptoms is still being debated. However, recent developments in surgical methods have shown promising results with using laser therapy as a minimally invasive treatment option. This procedure involves targeted removing damaged or diseased tissue using a laser while preserving the surrounding healthy tissue.
Topical Retinoid will account for a higher share of the market in the upcoming year
Topical retinoid is expected for a higher share throughout the forecast period. The main factor driving the market is anticipated to expand in the next years due to the efficiency of these drugs in treating the condition's symptoms. The possibility of skin irritability and other side effects from topical retinoids is one of the difficulties in this area. Consequently, novel formulations that lessen these adverse effects while maintaining efficacy may provide a competitive advantage.
For instance, the Nardin Hannaet al. research publication 2022 reports that DD has been reported to relapse following discontinuance or decreased frequency of treatment with oral retinoids, necessitating ongoing care. Many treatments have been employed to treat this disease in the literature, but the quality of the evidence still needs to improve. Several companies are currently developing new topical retinoid treatments for Darier disease, which are expected to increase the competition in the market. The growing number of clinical trials and research studies in this area also indicate a positive outlook for the topical retinoid market.
Dermatologist accounted for the largest share in 2022
Dermatologists held the largest market share in 2022. The main factor driving the market is that they play a critical role in managing this condition, as they are responsible for prescribing and monitoring treatments and providing patient education and support.
As the prevalence of Darier disease continues to increase, there is a growing demand for dermatologists who specialize in diagnosing and treating this condition. This has led to an increase in dermatologists focusing on rare skin diseases, such as Darier disease. As new treatments become available, dermatologists will play a crucial role in ensuring patients receive the most effective care possible. Furthermore, the growth in this segment is expected to drive improvements in patient outcomes and quality of life.
The demand in North America is expected to witness significant growth during forecast period
North America is expected to witness significant growth during the projected period. The market is expected to grow in the coming years due to several factors, including the increasing availability of healthcare services, rising healthcare expenditure, and increasing awareness of rare diseases among healthcare professionals and patients.
Additionally, developing new therapies and technologies for diagnosing and treating Darier disease is expected to drive growth. As for drug development in North America, many pharmaceutical companies have conducted clinical trials for various conditions, including Darier disease. In recent years, some companies in this region have been developing new drugs and treatments for the disease, including topical and gene therapies.
Competitive Insight
Some of the major players operating in the global market include AbbVie, Amneal Pharmaceuticals, Bausch Health Companies, BridgeBio Pharma, Galderma, GlaxoSmithKline, Glenmark Pharmaceuticals, Johnson and Johnson, Laminar Pharma, Mayne Pharma, Merck, Novartis, Pfizer, Sawai Pharmaceutical, Sigmapharm Laboratories, Sun Pharmaceutical, Teva Pharmaceutical, Tolmar Pharmaceuticals, Validus Pharmaceuticals, and Viatris.
Recent Developments
- In August 2019, Recursion Pharmaceuticals Inc. initiated pre-clinical trials for an undisclosed research project. The successful completion of these trials would potentially pave the way for the near-future evaluation of the undisclosed research project in individuals diagnosed with Darier disease.
Darier Disease Drug Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2023 |
USD 48.36 million |
|
Revenue forecast in 2032 |
USD 74.12 million |
|
CAGR |
4.9% from 2023– 2032 |
|
Base year |
2022 |
|
Historical data |
2019– 2021 |
|
Forecast period |
2023– 2032 |
|
Quantitative units |
Revenue in USD million and CAGR from 2023 to 2032 |
|
Segments covered |
By Treatment, By Application, By End-User, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
|
Key companies |
AbbVie, Amneal Pharmaceuticals, Bausch Health Companies, BridgeBio Pharma, Galderma S, GlaxoSmithKline Plc, Glenmark Pharmaceuticals, Johnson and Johnson, Laminar Pharma, Mayne Pharma Group, Merck and Co, Novartis AG, Pfizer, Sawai Pharmaceutical, Sigmapharm Laboratories LLC, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, Tolmar Pharmaceuticals, Validus Pharmaceuticals, and Viatris. |
FAQ's
The global darier disease market size is expected to reach USD 74.12 million by 2032.
top market players in the Darier Disease Market are AbbVie, Amneal Pharmaceuticals, Bausch Health Companies, BridgeBio Pharma, Galderma, GlaxoSmithKline, Glenmark Pharmaceuticals, Johnson and Johnson, Laminar Pharma.
North America contribute notably towards the global Darier Disease Market.
The global Darier disease market expected to grow at a CAGR of 4.9% during the forecast period.
The Darier Disease Market report covering key segments are treatment, application, end- user and region.
